Lepu Biopharmaceuticals: Estimated revenue of approximately 935 million yuan in 2025, with significant growth in sales of two core products

Recently, Lepu Biotech announced its 2025 performance report, stating that the company’s revenue achieved significant growth, reaching approximately 935 million yuan, about 2.5 times the revenue in 2024 (2024: 368 million yuan). Among them, domestic commercial sales of Puyuheng® (Pultealumab Injection) and Meiyouheng® (Vebecortumab Injection) totaled about 501 million yuan, a substantial increase of 66.8% compared to 2024 (2024: 300 million yuan). The company achieved a net profit of 261 million yuan for the year, marking its first full-year profit and a fundamental turnaround from a loss of 411 million yuan in 2024.

As of the announcement date, the company has two candidates in clinical/commercialization stages; eight candidates in clinical stages, including one developed jointly through a partnership; and five combination therapies involving our candidate drugs in clinical stages.

Two candidates have received approval for their targeted indications, while clinical trials for other indications are ongoing. Among the eight clinical-stage candidates, six are targeted therapies, and two are immunotherapies (including one oncolytic virus drug and one T-cell activating antibody).

Meiyouheng® (Vebecortumab Injection) has received approval for market launch from the National Medical Products Administration (NMPA) in China and has been granted Breakthrough Therapy Designation (BTD), Orphan Drug Designation (ODD), and Fast Track Designation (FTD) by the FDA for NPC. The combination therapy of Meiyouheng® (Vebecortumab Injection) and Pultealumab has been granted BTD by the NMPA’s Center for Drug Evaluation (CDE). MRG002 for the treatment of GC/GEJ has received ODD from the FDA. CMG901 for the treatment of GC/GEJ has received FTD and ODD from the FDA, and BTD from the NMPA’s CDE. MRG004A has been granted ODD and FTD by the FDA for the treatment of pancreatic cancer, as well as BTD from the NMPA’s CDE. MRG006A has received ODD and FTD from the FDA for the treatment of hepatocellular carcinoma. CG0070 has been granted BTD by both the NMPA’s CDE and the FDA. Additionally, Meiyouheng® (Vebecortumab Injection) and MRG006A have received IND approval from the FDA. The company continues to build and develop new technological platforms as its innovation engine, while promoting the ongoing progress of its pipeline of novel innovative molecules.

(Lepu Biotech Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical